Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1952-1963

  Saini, Sharanjot ^a   Majid, Shahana ^a   Shahryari, Varahram ^a   Tabatabai, Z Laura ^a   Arora, Sumit ^a   Yamamura, Soichiro ^a   Tanaka, Yuichiro ^a   Dahiya, Rajvir ^a   Deng, Guoren ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MICRORNA; MICRORNA 3607; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; ATTENUATION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE M PHASE; CELL INVASION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE CARCINOGENESIS; PROTEIN EXPRESSION; TUMOR GROWTH; CASTRATION RESISTANT PROSTATE CANCER; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SRC-FAMILY KINASES; TRANSFECTION;

EID: 84904170727     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0017     Document Type: Article

References (50)

1. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967-2000.
2. Brooks DD, Wolf A, Smith RA, Dash C, Guessous I. Prostate cancer screening 2010: updated recommendations from the American Cancer Society. J Natl Med Assoc 2010;102:423-9.
3. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98.
4. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710-21. (Pubitemid 351671887)
5. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232-41. (Pubitemid 46211560)
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
7. MacVicar GR, Hussain MH. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol 2013;25:252-60.
8. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
9. Ribeiro FR, Henrique R, Hektoen M, Berg M, Jeronimo C, Teixeira MR, et al. Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer 2006;5:33.
10. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancersmay contain aggressive genetic features. Am J Pathol 2001;158:399-406. (Pubitemid 32158603)
11. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56:3091-102. (Pubitemid 26199756)
12. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-7.
13. Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Hofler H, et al. Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 2001;84:202-8. (Pubitemid 32113447)
14. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996;56:4475-82. (Pubitemid 26330457)
15. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
16. Witten D, Tibshirani R, Gu SG, Fire A, Lui WO. Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls. BMC Biol 2010;8:58.
17. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18:1765-73. (Pubitemid 350119560)
18. Ingley E. Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal 2012;10:21.
19. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007;9:90-100.
20. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-33. (Pubitemid 37022641)
21. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001;21:8385-97. (Pubitemid 33108599)
22. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23:2197-205. (Pubitemid 38482534)
23. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004;64:7156-68. (Pubitemid 39331031)
24. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61. (Pubitemid 40053752)
25. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009;101:263-8.
26. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011;77:1166-71.
27. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421-8.
28. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, et al. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res 2011;17:5287-98.
29. Ting HJ, Hsu J, Bao BY, Lee YF. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Lett 2007;247:122-9. (Pubitemid 44959414)
30. Williams JF, Muenchen HJ, Kamradt JM, Korenchuk S, Pienta KJ. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate 2000;44:275-8.
31. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009;15:3540-9.
32. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33.
33. Bolen JB, Rowley RB, Spana C, Tsygankov AY. The Src family of tyrosine protein kinases in hemopoietic signal transduction. FASEB J 1992;6:3403-9. (Pubitemid 23007106)
34. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004;64:1058-66. (Pubitemid 38176910)
35. Bates RC, Edwards NS, Burns GF, Fisher DE. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 2001;61:5275-83. (Pubitemid 32681564)
36. Grishin AV, Azhipa O, Semenov I, Corey SJ. Interaction between growth arrest-DNA damage protein 34 and Src kinase Lyn negatively regulates genotoxic apoptosis. Proc Natl Acad Sci U S A 2001;98:10172-7. (Pubitemid 32802993)
37. Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999;13:855-61. (Pubitemid 29292134)
38. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000;106:1399-407.
39. Atfi A, Drobetsky E, Boissonneault M, Chapdelaine A, Chevalier S. Transforming growth factor beta down-regulates Src family protein tyrosine kinase signaling pathways. J Biol Chem 1994;269:30688-93. (Pubitemid 24376558)
40. Cardillo MR, Petrangeli E, Perracchio L, Salvatori L, Ravenna L, Di Silverio F. Transforming growth factor-beta expression in prostate neoplasia. Anal Quant Cytol Histol 2000;22:1-10. (Pubitemid 30106500)
41. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467-75.
42. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58. (Pubitemid 36791891)
43. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-80. (Pubitemid 38745532)
44. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19:5406-17.
45. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 1999;59:6145-52. (Pubitemid 30035635)
46. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9. (Pubitemid 41507982)
47. Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003;39:1927-35. (Pubitemid 37311191)
48. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 2001;20:1152-63. (Pubitemid 32226241)
49. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009;103:434-40.
50. Sanjay A, Houghton A, Neff L, Di Domenico E, Bardelay C, Antoine E, et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 2001;152:181-95. (Pubitemid 32102446)